Nomigrin (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium and sumatriptan succinate, the active ingredient in Nomigrin, is a combined NSAID and selective 5‑HT1B/1D receptor agonist presented as an oral tablet formulation for oral administration. The combination provides both anti‑inflammatory analgesia and targeted migraine relief, and it is used for the acute treatment of migraine attacks in adult patients.

GNH USA supplies Nomigrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and regulatory compliance for global distribution to meet local market requirements.

Nomigrin belongs to the NSAID and triptan drug families and is used to manage migraine episodes. - Acute migraine attacks: rapid relief of headache, nausea, photophobia and phonophobia. - Migraine with aura: alleviates the headache phase that follows visual or sensory aura symptoms. - Migraine without aura: reduces pain intensity and associated symptoms when taken early in the attack.

Common Side Effects: - Nausea or upset stomach - Dizziness or light‑headedness - Tingling or numbness in fingers or toes - Chest tightness or pressure - Flushing or warmth sensation - Dry mouth

Serious or Rare Side Effects: - Coronary artery spasm or myocardial ischemia - Severe allergic reaction (anaphylaxis, angioedema) - Serotonin syndrome when combined with other serotonergic agents - Gastrointestinal bleeding or ulcer perforation - Hepatic dysfunction or elevated liver enzymes - Stroke or transient ischemic attack

Before prescribing Nomigrin, clinicians should consider the following precautions: - Cardiovascular assessment: evaluate for coronary artery disease or uncontrolled hypertension. - Serotonergic risk: avoid in patients taking other triptans, SSRIs, SNRIs, or MAO inhibitors. - Gastro‑intestinal safety: use caution in patients with a history of ulcers or bleeding. - Renal or hepatic impairment: dose adjustment may be required. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nomigrin may interact with several drug classes. Major Interactions (Avoid): - SSRIs, SNRIs, or MAO inhibitors: increased risk of serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstrictive effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sumatriptan levels. Moderate Interactions (Monitor Closely): - Additional NSAIDs or aspirin: heightened gastrointestinal bleeding risk. - Antihypertensive agents (beta‑blockers, calcium channel blockers): may blunt blood pressure control.